In the 112-patient CheckMate 214 trial focusing on the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) intermediate- and poor-risk group, nivolumab plus ipilimumab, a CTLA-4 binder, showed improved efficacy with an ORR of 57% compared to just 19% with sunitinib alone [30]. The gene discussed is CTLA4; the disease is hereditary clear cell renal cell carcinoma.